Skip to main content
SpringerLink
Log in

Aggressive B cell lymphomas—highlights from ASH 2022

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The treatment landscape of aggressive B cell lymphomas has changed substantially in recent years. Several therapeutic agents changed the dogma of diffuse large B cell lymphoma (DLBCL) as a one shot cancer. CD-19-targeted CART cell therapy, CD79b-targeted antibody drug conjugate polatuzumab vedotin, and CD 19 antibody tafasitamab in combination with lenalidomide are approved in relapsed/refractory (r/r) disease. Recently the bispecific CD20/CD3 antibody glofitamab received approval for third-line therapy and approval for other CD20/CD3 bispecific antibodies is expected soon. This short review is a personal selection of the clinically most relevant abstracts besides CART therapy regarding aggressive B cell lymphomas presented at the 2022 ASH meeting in San Diego.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Illerhaus G et al. Effects on survival of non-myeloablative chemoimmunotherapy compared to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary cns lymphoma - results of an international randomized phase III trial (MATRix/IELSG43). Blood. 2022;140(suppl 2):LBA-3.

  2. Topp MS, et al. Glofitamab plus R‑CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B‑cell lymphoma (DLBCL): results from a phase Ib study. ASH 2022 abstract, Vol. 777. 2022.

    Google Scholar 

  3. Abrisqueta P, et al. Subcutaneous Epcoritamab + R‑Dhax/C in patients with relapsed or refractory diffuse large B cell lymphoma eligible for autologous stem cell transplant: updated phase 1/2 results. ASH 2022 abstract, Vol. 443. 2022.

    Google Scholar 

  4. Won-Seog K, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B‑cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM‑2. ASH 2022 Abtract, Vol. 444. 2022.

    Google Scholar 

  5. Dickinson MJ, et al. Glofitamab for relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2022;387(24):2220–31.

    Article  CAS  PubMed  Google Scholar 

  6. Hutchings M, et al. Relapse is uncommon in patients with large B‑cell lymphoma who are in complete remission at the end of fixed-course Glofitamab treatment. ASH 2022 Abstract, Vol. 441. 2022.

    Google Scholar 

  7. Kater AP, et al. Subcutaneous Epcoritamab in patients with richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). ASH 2022 abstract, Vol. 348. 2022.

    Google Scholar 

  8. Duell J, et al. Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L‑MIND study. AACR 2023 abstract, Vol. CT022. 2023.

    Google Scholar 

  9. Qualls D, et al. Tafasitamab and Lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): real world outcomes in a multicenter retrospective study. ASH 2022 abstract, Vol. 323. 2022.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Heinrich Collin Str. 30, 1140, Vienna, Austria

    Michael Panny

Authors
  1. Michael Panny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Panny.

Ethics declarations

Conflict of interest

M. Panny has received honoraria from Roche and Abbvie.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panny, M. Aggressive B cell lymphomas—highlights from ASH 2022. memo 16, 149–151 (2023). https://doi.org/10.1007/s12254-023-00908-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00908-y

Keywords

Search

Navigation